Humana Inc.

Valuation Analysis

About the Company

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care center

Humana Inc. Stock at a Glance

Humana Inc. (HUM) is currently trading at $379.22 with a market capitalization of $45.5B. The trailing P/E ratio stands at 40.47x, with a forward P/E of 24.1x. The 52-week range spans from $163.11 to $379.50; the current price is 0.1% below the yearly high. Year-over-year revenue growth stands at +23.5%. The net profit margin stands at 0.82%.

💰 Dividend

Humana Inc. pays an annual dividend of $3.54 per share, representing a yield of 0.93%. The payout ratio stands at 37.78%.

📊 Analyst Rating

24 analysts rate Humana Inc. (HUM) on consensus: Hold. The average price target is $301.62, implying -20.46% from the current price. Analyst price targets range from $195.00 to $441.00.

Humana Inc.: The Investment Case in Detail

Humana Inc. (HUM) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 23.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power.

The Bear Case

With a net margin of just 0.82%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

What to Watch Next

• The forward P/E of 24.1x is meaningfully below the trailing 40.47x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 99.9% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (5.79%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Humana Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.